A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

What this study is about

The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic colorectal cancer

Who can join (things the study team will check)

✅ You may be able to join if…

• Participant must previously untreated, histologically confirmed recurrent or metastatic colorectal adenocarcinoma, not amenable to curative surgery.
• Participant must have no known presence of mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC) per historical results (a validated test should be used).
• Participant must have no known presence of the gene that encodes the protein B-Raf (BRAF) V600E mutation per local testing.
• Participant must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

🚫 You may not be able to join if…

• Participant must not have any untreated known central nervous system (CNS) metastases including brain, leptomeningeal and/or spinal cord compression.
• Participant must not have any prior malignancy active within the previous 2 years, except for locally curable cancers that have been apparently cured and considered to be of low risk of recurrence.
• Participant must not have significant cardiovascular disease, such as myocardial infarction, unstable angina, arterial thrombosis or cerebrovascular accident within 6 months prior to randomization, uncontrolled hypertension (≥ 160 systolic, and/or ≥ 100 diastolic mm Hg) despite optimal medical management, or congenital long QT syndrome.
• Participant must not have prior systemic treatment with an anti-PD-1, anti-programmed death (ligand)-1 (PD-L1), anti-PD-L2, CD137 agonists, or anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T cell co-stimulation or checkpoint pathways or chemotherapy.
• Other protocol-defined Inclusion/Exclusion criteria apply.

Where this trial is running

• Local Institution - 0428, Tucson, Arizona, United States
• Highlands Oncology Group, Springdale, Arkansas, United States
• Local Institution - 0447, La Jolla, California, United States
• USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
• University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange, California, United States
• Local Institution - 0317, San Francisco, California, United States
• Local Institution - 0330, Santa Monica, California, United States
• Local Institution - 0293, Stanford, California, United States
• Florida Cancer Specialists - East, Cape Coral, Florida, United States
• Florida Cancer Specialists - North, St. Petersburg, Florida, United States
• Moffitt Cancer Center, Tampa, Florida, United States
• Northside Hospital, Atlanta, Georgia, United States

+ 275 more sites.

Who to contact

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07221357.